|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Ergomed Opens New Facility in Russia
ERGOMED Group, a specialised international clinical development company, today announced that it has opened a new facility in Russia. At the same time, ERGOMED is appointing Dr. Sergei Drapkin as the Managing Director for the Russian office.
The new office, which strengthens ERGOMED's position in Eastern Europe and Central Asia, will support ongoing operations in Russia, Ukraine, Kazakhstan and Belorussia. These countries represent emerging regions with very significant potential for high patient recruitment. Clinical research in ERGOMED's areas of specialisation in these regions is also of a high quality given the generally high standard of medical training and the concentration of medical expertise in a few centres.
Dr. Miroslav Reljanovic, CEO of the ERGOMED Group, commented, "We have been carrying out clinical trials in Eastern Europe for some years now and have successfully integrated our Study Site Management system in Central and Eastern Europe, delivering faster patient recruitment and improved data quality. We are especially excited to be bringing advanced technologies in clinical research in this emerging region and we certainly think this is achievable, given our approach supported by our experienced Managing Director for this area, Dr. Sergei Drapkin. We are pleased to welcome him to the ERGOMED Group."
Dr. Sergei Drapkin, the new Managing Director for the Russian office, added, "The Russian region is a key emerging region for clinical research and ERGOMED is pioneering highly effective strategies such as Study Site Management. I am therefore proud to have been appointed as the Managing Director for ERGOMED Russia and to have the opportunity to establish the office in Moscow."
About ERGOMED Group
ERGOMED is a specialised international clinical development company offering contract clinical research and co-development partnerships to biotechnology and pharmaceutical companies worldwide in the fields of neurology, oncology and immunology. ERGOMED's approach to clinical research ensures effective patient recruitment, reducing the time and costs of clinical trials and complementing the drug discovery capabilities of its customers and partners. The Company has a dual business model offering standard clinical trial management contracts and also co-development partnerships to share the risks and rewards of clinical development. ERGOMED is headquartered in Frankfurt, Germany, and has offices throughout Europe and in USA. For further information visit www.ergomed-cro.com
About Dr. Sergei Drapkin
Before joining ERGOMED Russia as Managing Director, Dr. Sergei Drapkin served in senior management roles within international CROs. From 1997 Dr. Drapkin worked for Quintiles Transnational Corp., where he co-founded Quintiles' Moscow office. Over a decade at Quintiles, he led a wide variety of clinical research programmes - from small pilot projects to multi-center, multi-country large scale trials overseeing studies with hundreds of sites and thousands of patients. In particular, Dr. Drapkin headed the Quintiles' strategic group for assessing the feasibility of clinical research programmes in Central and Eastern Europe and the Middle East. He received his medical degree from Moscow Medical Sechenov Academy in 1992 followed by five years of specialisation in cardiology and urgent care medicine at Russia's Premier